Bayesian Capital Management, LP Puma Biotechnology, Inc. Transaction History

Bayesian Capital Management, LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$2.12 - $5.08 $25,230 - $60,457	11,901 New	11,901 $50,000
Q3 2020 Nov 12, 2020	SELL	$9.5 - $11.14 $101,650 - $119,198	-10,700 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$7.01 - $13.24 $75,007 - $141,668	10,700 New	10,700 $112,000
Q1 2020 May 15, 2020	SELL	$6.28 - $14.57 $106,879 - $247,966	-17,019 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$6.5 - $10.73 $110,623 - $182,613	17,019 New	17,019 $149,000
Q3 2019 Nov 13, 2019	SELL	$8.75 - $12.85 $131,250 - $192,750	-15,000 Closed	0 $0
Q2 2019 Aug 13, 2019	SELL	$12.3 - $35.76 $43,972 - $127,842	-3,575 Reduced 19.25%	15,000 $191,000
Q1 2019 May 14, 2019	BUY	$20.77 - $42.37 $385,802 - $787,022	18,575 New	18,575 $721,000
Q2 2018 Aug 14, 2018	SELL	$48.3 - $68.25 $362,250 - $511,875	-7,500 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$59.7 - $99.25 $447,750 - $744,375	7,500 New	7,500 $510,000

102

29.1M

60.6K

16.3K

Ticker PBYI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,556,000
Market Cap $128M
Description
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for...

Get notified when there are updates to the investment portfolio of Bayesian Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Bayesian Capital Management, LP with notifications on news.